![Chris Richard](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 561 938 $ in data 30/09/2026
Christian M.
Richard is currently Director at Amphivena Therapeutics, Inc. and Rainier Therapeutics, Inc. Mr. Richard serves as Independent Director at Cypherpunk Technologies, Inc. since 2023.
Mr. Richard is Portfolio Manager at Monashee Investment Management LLC starting in 2024.
Formerly, Mr. Richard was Senior Vice President of Research at Tekla Capital Management LLC from 2015 to 2020.
Mr. Richard was Partner & Head of Research at Merlin Nexus from 2004 to 2015.
Mr. Richard worked as Associate Research Scientist at Schering-Plough Research Institute from 1997 to 2001.
Mr. Richard completed graduate and Masters of Business Administration degrees at New York University.
Mr. Richard earned an undergraduate degree from Purchase College in 1993.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/07/2026 | 168.750 ( 0,16% ) | 561 938 $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. | Direttore/Membro del Consiglio | 17/01/2023 |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer | Direttore/Membro del Consiglio | - |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. BiotechnologyHealth Technology Develops clinical-stage immuno-oncology therapeutics | Direttore/Membro del Consiglio | - |
Monashee Investment Management LLC
 Monashee Investment Management LLC Investment ManagersFinance Monashee seeks to provide consistently stronger returns than the broader equity markets by investing systematically in the equity and convertible debt securities of companies raising new equity capital globally or via secondary offerings, block trades, registered direct offerings and PIPEs where a significant shareholder seeks to sell a secondary position. The firm will seek to capture the discount inherent in equity new issues, including both offerings by companies that are already publicly traded (follow-ons) and initial public offerings (IPOs). | Gestore di Portafoglio-Azioni | 01/09/2024 |
| Società | Posizione | Fine |
|---|---|---|
Tekla Capital Management LLC
 Tekla Capital Management LLC Investment ManagersFinance Tekla primarily focuses on healthcare investing. Their funds invest in public and private growth equities in the healthcare and life sciences industries. | Analyst-Equity | 01/11/2020 |
Merlin Nexus
 Merlin Nexus Investment ManagersFinance Merlin Nexus invests in both private and public life sciences companies across the globe. The firm focuses on sectors such as biotechnology, medical devices, molecular diagnostics, and specialty pharmaceuticals. It participates in late-stage and PIPE (Private Investments in Public Equity) transactions. | Analista di Private Equity | 28/02/2015 |
Schering-Plough Research Institute
 Schering-Plough Research Institute Medical SpecialtiesHealth Technology Provides pharmaceutical research | Corporate Officer/Principal | 31/12/2001 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 9 |
|---|---|
Tekla Capital Management LLC
Tekla Capital Management LLC Investment ManagersFinance Tekla primarily focuses on healthcare investing. Their funds invest in public and private growth equities in the healthcare and life sciences industries. | Finance |
New York University
 New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merlin Nexus
Merlin Nexus Investment ManagersFinance Merlin Nexus invests in both private and public life sciences companies across the globe. The firm focuses on sectors such as biotechnology, medical devices, molecular diagnostics, and specialty pharmaceuticals. It participates in late-stage and PIPE (Private Investments in Public Equity) transactions. | Finance |
Schering-Plough Research Institute
Schering-Plough Research Institute Medical SpecialtiesHealth Technology Provides pharmaceutical research | Health Technology |
Purchase College
 Purchase College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monashee Investment Management LLC
Monashee Investment Management LLC Investment ManagersFinance Monashee seeks to provide consistently stronger returns than the broader equity markets by investing systematically in the equity and convertible debt securities of companies raising new equity capital globally or via secondary offerings, block trades, registered direct offerings and PIPEs where a significant shareholder seeks to sell a secondary position. The firm will seek to capture the discount inherent in equity new issues, including both offerings by companies that are already publicly traded (follow-ons) and initial public offerings (IPOs). | Finance |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. BiotechnologyHealth Technology Develops clinical-stage immuno-oncology therapeutics | Health Technology |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer | Health Technology |
Leap Therapeutics, Inc.
 Leap Therapeutics, Inc. Financial ConglomeratesFinance Operates as a digital asset treasury company | Finance |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
